According to Cara Therapeutics 's latest financial reports the company's current revenue (TTM) is $20.96 M. In 2022 the company made a revenue of $41.86 M an increase over the years 2021 revenue that were of $23.02 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $20.96 M | -49.92% |
2022 | $41.86 M | 81.81% |
2021 | $23.02 M | -82.95% |
2020 | $0.13 B | 579.28% |
2019 | $19.88 M | 47.64% |
2018 | $13.46 M | 1378.49% |
2017 | $0.91 M | 959.3% |
2016 | $0.08 M | -97.74% |
2015 | $3.8 M | 19.7% |
2014 | $3.17 M | -73.45% |
2013 | $11.96 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 443,537.92% | ๐บ๐ธ USA |
Pfizer PFE | $58.49 B | 278,882.26% | ๐บ๐ธ USA |
Trevena TRVN | $3.2 M | -84.71% | ๐บ๐ธ USA |
Recro Pharma
REPH | $75.36 M | 259.40% | ๐บ๐ธ USA |
Flexion Therapeutics
FLXN | $0.10 B | 378.82% | ๐บ๐ธ USA |
Acorda Therapeutics
ACOR | $0.11 B | 461.01% | ๐บ๐ธ USA |
AcelRx Pharmaceuticals
ACRX | $0.65 M | -96.90% | ๐บ๐ธ USA |